Eaton Vance Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Eaton Vance Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$393K	Sell	15,641 -8	-0.1%	-$222	﹤0.01%	1382
2022 Q2	$476K	Sell	15,649 -12,152	-44%	-$363K	﹤0.01%	1380
2022 Q1	$911K	Buy	27,801 +12,152	+78%	+$361K	﹤0.01%	1388
2021 Q4	$413K	Hold	15,649	–	–	﹤0.01%	1368
2021 Q3	$1.57M	Hold	15,649	–	–	﹤0.01%	986
2021 Q2	$2.21M	Sell	15,649 -277	-2%	-$31.3K	﹤0.01%	988
2021 Q1	$1.59M	Buy	15,926 +285	+2%	+$33.2K	﹤0.01%	1025
2020 Q4	$1.93M	Sell	15,641 -18	-0.1%	-$2.37K	﹤0.01%	937
2020 Q3	$1.53M	Hold	15,659	–	–	﹤0.01%	903
2020 Q2	$2.44M	Buy	15,659 +18	+0.1%	+$2.74K	0.01%	765
2020 Q1	$2.26M	Hold	15,641	–	–	0.01%	735
2019 Q4	$3.2M	Buy	15,641 +4,694	+43%	+$856K	0.01%	731
2019 Q3	$879K	Hold	10,947	–	–	﹤0.01%	1001
2019 Q2	$1.03M	Buy	+10,947	New	+$945K	﹤0.01%	950

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eaton Vance Management's RETA Position: Q3 2022 in Review

Eaton Vance Management reduced its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 0.05% in Q3 2022, selling an estimated $222 and leaving 15,641 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #1382.

Eaton Vance Management first reported a position in RETA in Q2 2019 and has held it in 14 quarters since. The position peaked at $3.2M in Q4 2019. 158 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

Eaton Vance Management held 15,641 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $393K as of Q3 2022.
Eaton Vance Management sold 8 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $222.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1382 holding.
Eaton Vance Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and has held it in 14 quarters since.
Eaton Vance Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.2M in Q4 2019.
158 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.